Candiolo Cancer Institute IRCCS

What Candiolo Cancer Institute IRCCS does

Candiolo Cancer Institute IRCCS, operating as INOC - Istituto Nazionale Oncologico Candiolo, is a private nonprofit Scientific Institute for Hospitalization and Healthcare Research (IRCCS) located in Candiolo, Piedmont, Italy. It is the only oncological IRCCS in the Piedmont region recognized by the Italian Ministry of Health and has held OECI Comprehensive Cancer Centre certification since 2022. The institute delivers integrated cancer care across the full continuum — diagnosis, surgery, medical oncology, radiotherapy, nuclear medicine, stem cell transplantation, immunotherapy, palliative care, and psychological support — organized into 41 research and care units and supported by 560 healthcare professionals and 266 researchers. It treats approximately 37,000 patients and 3,215 hospitalizations annually, producing 230 scientific publications in 2025, with a dedicated Phase I Clinical Trials Unit enabling access to experimental therapies.

The institute's core technology platform combines advanced diagnostic imaging, nuclear medicine, radiotherapy, laboratory analysis, pathological anatomy, and digestive endoscopy with translational research workflows that translate scientific discoveries into clinical applications. Products are organized as specialized clinical divisions — Breast Unit, Centro Trapianti, Immunoterapia Oncologica, Radioterapia, Medicina Nucleare, Unità Clinica di Fase I, Clinical Research Unit, and Hospice Monviso — alongside a digital online booking system for patient access. Differentiators include multidisciplinary specialist programs spanning solid tumors, hematological malignancies, and rare cancers; a referral-based integration with the Rete Oncologica di Piemonte e Valle d'Aosta; and OECI-accredited integrated care from diagnosis through follow-up.

The business model is anchored in reimbursement from the Italian National Health Service (SSN) under universal coverage, supplemented by private consultations, research grants (national and international), and clinical trial contracts. Patients access services primarily through SSN referral from the regional oncology network or via the online booking platform for private-pay visits. The institute rebranded to INOC in 2026 to signal expansion of scope from regional to national, supported by a partnership network that includes the OECI, regional oncology network, Casa di Accoglienza La Madonnina ONLUS for family accommodation, and the SSN itself as the principal payer.

Name

Candiolo Cancer Institute IRCCS

Legal name

INOC - Istituto Nazionale Oncologico Candiolo

Website

https://irccs.org

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

251–500 employees

Short description

INOC (Candiolo Cancer Institute IRCCS) is an Italian nonprofit comprehensive cancer centre in Piedmont providing integrated oncological diagnosis, treatment, and translational research across 41 units, serving 37,000 patients annually through the Italian National Health Service.

Ownership category

akta.pro rank

Product category

Oncology Hospital and Research Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), General Medical and Surgical Hospitals (6221), Offices of Physicians (62111), Medical and Diagnostic Laboratories (62151), Diagnostic Imaging Centers (621512)

SIC

Services-Health Services (8000), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

akta.pro secondary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Cancer treatment services
• Oncology research
• Clinical trials
• Precision medicine
• Translational oncology

Headquarters

HQ city

Candiolo

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. National Health Service (SSN) Reimbursement: Public healthcare services funded through the Italian National Health Service, providing diagnosis, treatment, and care for cancer patients under universal coverage
2. Private Healthcare Services: Private consultations and services for patients choosing non-SSN pathways
3. Research Grants and Funding: National and international research project funding, including grants from the Grant Office and support for clinical research

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Candiolo Cancer Institute IRCCS is a specialized Italian oncology hospital and research center that delivers comprehensive cancer prevention, diagnosis, treatment, and follow-up care alongside translational and clinical cancer research. It operates as an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) recognized by the Italian Ministry of Health and integrates inpatient care, outpatient clinics, research laboratories, and clinical trial programs under a single institution.

Product overview

INOC - Istituto Nazionale Oncologico Candiolo is a Comprehensive Cancer Centre (IRCCS) providing integrated oncological care through a unified healthcare delivery platform. The institute operates multiple specialized clinical divisions including medical oncology, surgical oncology, radiotherapy, nuclear medicine, and immunotherapy, supported by dedicated units such as the Breast Unit, Centro Trapianti di cellule staminali emopoietiche, Unità Clinica di Fase I, and Clinical Research Unit. Patient services include an online booking system for appointments and a palliative care hospice (Hospice Monviso). The organization combines clinical care with translational research to advance cancer treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer diagnosis and inpatient treatment Hospital-based diagnostic workup, surgical oncology, medical oncology, and inpatient care for cancer patients delivered through the Italian National Health Service.
• Outpatient oncology clinics Specialized outpatient consultations, follow-up visits, and day-hospital services for cancer patients, including private (solvent) consultations.
• Clinical cancer research and laboratory programs Translational and laboratory research programs in oncology conducted by institute researchers across dedicated research units.
• Clinical trials for cancer patients Experimental and first-in-human clinical trial protocols offered to cancer patients as part of the institute's research-to-care mission.
• Cancer screening and prevention services Programs for cancer screening, early detection, hereditary cancer risk assessment, and prevention delivered by the institute.

Quantifiable outcome

• 37,000 patients treated in 2025
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• European Organization of Cancer Institutes (OECI)coreStrategic or Co-development Partner · 1 January 2022OECI granted INOC the Comprehensive Cancer Centre certification in 2022, recognizing the institute's excellence in providing integrated multidisciplinary cancer care from diagnosis to treatment and psychological support. This certification positions INOC among elite European cancer centers.
• Rete Oncologica di Piemonte e Valle d'AostacoreStrategic or Co-development PartnerINOC is an integral part of the Piedmont and Aosta Valley Oncology Network, serving as a specialized referral center for complex cancer cases requiring multidisciplinary treatment approaches not available at smaller regional facilities.
• Casa di Accoglienza La Madonnina ONLUSsupportingOthersNon-profit accommodation facility located in Candiolo providing 27 rooms and common spaces for patients' families requiring temporary housing during treatment periods. Part of INOC's solidarity hospitality program.
• Italian National Health Service (SSN)coreStrategic or Co-development PartnerINOC operates as a public IRCCS institution within the Italian healthcare system, providing universal cancer care coverage funded through the national health service reimbursement system.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Charité Comprehensive Cancer Center: Charité CCC is a German OECI-certified comprehensive cancer center integrating university hospital oncology with translational research. Like INOC, it combines clinical care, Phase I trials, and academic publishing, though at substantially larger scale.
• Netherlands Cancer Institute (NKI): NKI is an OECI-certified comprehensive cancer center combining independent research with clinical oncology in Amsterdam. Comparable to INOC in its research-clinical integration model, it competes internationally for translational research funding and oncology trial enrollment.
• The Royal Marsden NHS Foundation Trust: Royal Marsden is a UK-based comprehensive cancer center with strong translational research and Phase I trial activity. Its integrated research-clinical model and OECI membership make it a directly comparable European peer in cancer center operations.
• Gustave Roussy Comprehensive Cancer Center: Gustave Roussy is one of Europe's largest comprehensive cancer centers and OECI-certified, headquartered near Paris. It is a broad incumbent peer in translational oncology, Phase I trials, and integrated multidisciplinary cancer care, competing with INOC for international trial placement and academic visibility.
• Vall d'Hebron Institute of Oncology (VHIO): VHIO is a Spanish comprehensive cancer center affiliated with the Vall d'Hebron University Hospital, focused on translational oncology and early-phase clinical trials. Its research-clinical integration model and European positioning make it a comparable peer.

Direct peers

• IRCCS Ospedale San Raffaele: San Raffaele is a Milan-based IRCCS combining clinical care with translational research, including a significant oncology and hematology program with stem cell transplantation. Its integrated research-hospital model and Italian IRCCS status make it a directly comparable peer.
• Istituto Europeo di Oncologia (IEO): IEO is a Milan-based comprehensive cancer center and IRCCS operating under a similar Italian public/private model with multidisciplinary oncological care, translational research, and SSN reimbursement. It is the closest direct comparable to INOC in terms of scope, regulatory status, and clinical-research integration.
• Fondazione IRCCS Istituto Nazionale dei Tumori (INT): INT Milan is Italy's flagship national oncology IRCCS, providing comprehensive cancer care and clinical research across all major tumor types. Like INOC, it combines SSN-funded clinical activity with translational research and Phase I trial capabilities, making it a directly comparable Italian peer.
• European Institute of Oncology (IEO) Foundation: For international benchmarking, Memorial Sloan Kettering Cancer Center represents the gold-standard translational oncology center. While much larger in scale, it is a comparable peer in operating model—research-hospital integration, Phase I trial leadership, and academic publication output—and serves as the upper-bound benchmark for INOC's clinical-research ambitions.
• IFOM - FIRC Institute of Molecular Oncology: IFOM is a Milan-based molecular oncology research institute closely affiliated with IEO. It mirrors INOC's translational research integration and is a peer in the Italian oncology research ecosystem, with overlapping talent and publication pipelines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@inoc_candiolo
• Facebookfacebook.com/istitutodicandiolo
• LinkedInlinkedin.com/company/candiolocancerinstitute
• Instagraminstagram.com/inoc_candiolo
• Xx.com/fpoirccs

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Candiolo Cancer Institute IRCCS